GIGLogo_Color_Horizontal.jpg
Global Indemnity Group, LLC Reports Third Quarter 2020 Results
November 09, 2020 08:02 ET | Global Indemnity Group, LLC
BALA CYNWYD, Pa., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Global Indemnity Group, LLC (NASDAQ:GBLI) (the “Company”) today reported a net loss of $22.2 million for the nine months ended September 30, 2020...
Nkarta.png
Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer
November 09, 2020 08:02 ET | Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Celldex Logo.jpg
Celldex Presents Data from Oncology Portfolio at SITC 2020
November 09, 2020 08:01 ET | Celldex Therapeutics, Inc.
-- Agonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated----Axl and CDX-527 programs highlighted-- HAMPTON, N.J., Nov. 09, 2020 (GLOBE...
Genocea Logo_RGB.jpg
Genocea Presents Positive GEN-009 Clinical Results, Update on GEN-011 Program and New InhibigenTM Mechanism of Action Data at Virtual SITC 2020
November 09, 2020 08:01 ET | Genocea Biosciences, Inc.
Novel clinical and durable immune response patterns suggest addition of GEN-009 may offer additive clinical benefit in combination with PD-1-based therapies GEN-011, a neoantigen-targeted peripheral...
allakos.jpg
Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update
November 09, 2020 08:01 ET | Allakos Inc.
REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast...
advaxis-squarelogo-1498831554460.png
Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 09, 2020 08:01 ET | Advaxis, Inc.
Disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression on KEYTRUDA® Biomarker data confirms on-mechanism activation of innate...
AGI Logo.jpg
Aspen Group, Inc. Announces Q2 FY’2021 Quarterly Enrollments Increased 20% to a Record 2,659 New Students; Quarterly Bookings Grew by 34% to $42.1 Million
November 09, 2020 08:01 ET | Aspen Group Inc.
AGI’s Total Active Student Body Rises Sequentially by Over 1,100 Students to 13,238; Nursing Active Student Body Grows Sequentially by Over 1,000 Students to 11,442 or 86% of Total Management to...
logo.png
Netfin Acquisition Corp. Announces Positive Results of Shareholder Redemptions
November 09, 2020 08:00 ET | Netfin Acquisition Corp
- Approximately $250 Million in Cash Will Remain in Trust Account -- Less Than 3% of Public Shares Elected Redemption -- Shareholders Are Reminded to Vote in Favor of the Business Combination - NEW...
patriot_one_for_pr3.jpg
Patriot One Appoints Peter Evans as CEO
November 09, 2020 08:00 ET | Patriot One Technologies Inc
TORONTO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Patriot One Technologies Inc. (TSX: PAT) (OTCQX: PTOTF) (FRANKFURT: 0PL) (“Patriot One” or the “Company”)  is pleased to announce the appointment of Peter...
logo_02.jpg
Ipsidy Announces Results for Third Quarter Ended September 30, 2020
November 09, 2020 08:00 ET | Ipsidy Inc
LONG BEACH, N.Y., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Ipsidy Inc. (www.ipsidy.com) [OTCQB:IDTY] a leading provider of secure, mobile biometric identity solutions, including Identity as a Service...